topline results

Kyverna Therapeutics (NASDAQ: KYTX) will host a live webcast and conference call on Dec 15, 2025 at 8:00 a.m. ET to present topline data from its registrational Phase 2 KYSA‑8 trial of the CD19 CAR‑T therapy KYV‑101 in stiff‑person syndrome. Registration is required for dial‑in details; the webcast and slides will be available on the investor‑relations site afterward. Ahead of the call, KYTX shares closed at $8.78, rose 5.0% on elevated volume, and the company cites a $150 M non‑dilutive loan and $171 M cash runway supporting a planned BLA filing in early 2026.